Skip to contentA
Aclaris Therapeutics, Inc.
A
ACRSAclaris Therapeutics, Inc. Q3 2022 · 10-Q
Revenue$19.02M$19.02M+1,046.4% vs Q3 2021 Net Income-$19.95M-$19.95MN/M vs Q3 2021 EPS Diluted-$0.30-$0.30N/M vs Q3 2021 Operating Income-$20,874,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aclaris Therapeutics, Inc. · CIK 1557746 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$7,967,000N/M Margins · derivedOperating margin-109.8%+1113.6 pt vs Q3 2021
Net margin-104.9%+1169.7 pt vs Q3 2021
ended Sep 30, 2022 · filed Nov 8, 2022 · 39 d after period end